Immatics N.V. (NASDAQ:IMTX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Immatics N.V. (NASDAQ:IMTX) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $20.80.

IMTX has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. TD Cowen began coverage on shares of Immatics in a research note on Tuesday, April 28th. They set a “buy” rating for the company. Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of Immatics in a research report on Tuesday, May 19th. Finally, Weiss Ratings downgraded shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd.

Immatics Price Performance

Shares of NASDAQ:IMTX opened at $8.55 on Friday. The business’s 50 day moving average price is $9.48 and its 200-day moving average price is $10.05. Immatics has a 1 year low of $5.05 and a 1 year high of $12.41. The firm has a market capitalization of $1.15 billion, a PE ratio of -4.60 and a beta of 1.33.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Immatics had a negative return on equity of 47.41% and a negative net margin of 495.71%.The company had revenue of $10.44 million for the quarter, compared to analyst estimates of $12.42 million. As a group, analysts expect that Immatics will post -1.76 earnings per share for the current year.

Institutional Investors Weigh In On Immatics

Several large investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. grew its position in Immatics by 10.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock valued at $225,322,000 after buying an additional 2,075,987 shares during the last quarter. RTW Investments LP boosted its stake in shares of Immatics by 29.7% during the 4th quarter. RTW Investments LP now owns 11,433,354 shares of the company’s stock worth $120,050,000 after acquiring an additional 2,617,737 shares in the last quarter. Perceptive Advisors LLC grew its holdings in Immatics by 10.7% in the fourth quarter. Perceptive Advisors LLC now owns 10,383,456 shares of the company’s stock valued at $109,026,000 after purchasing an additional 1,000,000 shares during the last quarter. Vestal Point Capital LP increased its holdings in Immatics by 1.6% during the 3rd quarter. Vestal Point Capital LP now owns 6,350,000 shares of the company’s stock valued at $54,102,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Jefferies Financial Group Inc. raised its position in shares of Immatics by 323.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 5,059,551 shares of the company’s stock worth $53,125,000 after purchasing an additional 3,864,636 shares during the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.